Krystal Biotech Inc (KRYS)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 95,356 | 12,897 | -139,975 | -69,570 | -32,167 |
| Revenue | US$ in thousands | 296,569 | 55,764 | 498 | — | — |
| Pretax margin | 32.15% | 23.13% | -28,107.43% | — | — |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $95,356K ÷ $296,569K
= 32.15%
Krystal Biotech Inc's pretax margin has shown significant fluctuations over the years. In December 31, 2022, the pretax margin was at a concerning -28,107.43%, indicating that the company incurred substantial losses before tax during that period. However, the following years saw a positive turnaround in the company's performance, with the pretax margin improving to 23.13% in December 31, 2023, and further increasing to 32.15% in December 31, 2024. This suggests that Krystal Biotech Inc has been able to enhance its operational efficiency and profitability, leading to healthier financial performance in more recent years. It is crucial for the company to sustain this positive trend to ensure long-term financial sustainability and growth.
Peer comparison
Dec 31, 2024